<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905657</url>
  </required_header>
  <id_info>
    <org_study_id>3475-010</org_study_id>
    <secondary_id>2012-004391-19</secondary_id>
    <secondary_id>132355</secondary_id>
    <secondary_id>MK-3475-010</secondary_id>
    <nct_id>NCT01905657</nct_id>
  </id_info>
  <brief_title>Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)</brief_title>
  <official_title>A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared two doses of pembrolizumab (MK-3475) versus docetaxel in participants
      with non-small cell lung cancer (NSCLC) who had experienced disease progression after
      platinum-containing systemic therapy. Participants were assigned randomly to receive either
      pembrolizumab 2 mg/kg once every three weeks (Q3W), pembrolizumab 10 mg/kg Q3W or docetaxel
      75 mg/m^2 Q3W. This study used an adaptive trial design so that the total number of
      participants randomized depended upon demonstration of sufficient objective responses at an
      interim analysis.

      Protocol Amendment 12 (effective date: 09 Dec 2015) enabled eligible participants who were
      allocated to docetaxel and experienced disease progression, to be permitted to crossover to
      receive pembrolizumab 2 mg/kg Q3W as long as Inclusion/Exclusion criteria were met. These
      participants were participating in the Cross-Over Phase. With Protocol Amendment 15
      (effective date: 03 Jan 2018), all second course and crossover participants will receive
      pembrolizumab 200 mg Q3W. Also with Amendment 15, once a participant has achieved the study
      objective or the study has ended, the participant will be discontinued from this study and
      enrolled in an extension study to continue protocol-defined assessments and treatment.
      Crossover participants who have not transitioned to pembrolizumab will be considered for the
      extension study on a case-by-case basis.

      The primary study hypotheses are that pembolizumab prolongs Overall Survival (OS) and
      Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1
      (RECIST 1.1) by independent radiologists' review in previously-treated participants with
      NSCLC in the strongly positive programmed cell death ligand 1 (PD-L1) stratum compared to
      docetaxel and in participants whose tumors express PD-L1 compared to docetaxel.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 9, 2013</start_date>
  <completion_date type="Anticipated">March 29, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through database cutoff date of 30 Sep 2015 (Approximately 23 months)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. OS was analyzed using the Kaplan-Meier method and is reported in months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Through database cutoff date of 30 Sep 2015 (Approximately 23 months)</time_frame>
    <description>PFS was defined as the time from the first day of study treatment to the first documented disease progression per RECIST 1.1 based on blinded independent central radiologists' review or death due to any cause, whichever occurred first. Using RECIST 1.1, progressive disease was defined as either a 20% relative increase in the sum of diameters of target lesions, taking as reference the smallest sum on study OR an absolute increase of &gt;5 mm in the sum of lesions, OR the appearance of new lesions. PFS was analyzed using the Kaplan-Meier method and is reported in months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>AEs: Up to 30 days after last dose of study drug (Up to approximately 24 months). Serious AEs: Up to 90 days after last dose of study drug (Up to approximately 27 months).</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the study drug, was also an AE. After discontinuation of study drug, each participant was monitored for a minimum of 30 days after last dose of study drug (serious AEs were monitored for up to 90 days after last dose of study drug).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinuing Study Drug Due to AEs</measure>
    <time_frame>Up to approximately 23 months</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the study drug, was also an AE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by RECIST 1.1</measure>
    <time_frame>Through database cutoff date of 30 Sep 2015 (Approximately 23 months)</time_frame>
    <description>ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) based on blinded independent central radiologists' review using RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) by RECIST 1.1</measure>
    <time_frame>Through database cutoff date of 30 Sep 2015 (Approximately 23 months)</time_frame>
    <description>DOR is measured from the time measurement criteria were first met for CR/PR (whichever was first recorded) until the first date that recurrent or progressive disease was objectively documented (taking as reference for progressive disease the smallest measurements recorded on study). DOR was censored at the last tumor assessment date if a responder did not have PD or death. Non-responders were not included in the analysis. DOR was analyzed using the Kaplan-Meier method and is reported in weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1061</enrollment>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 75 mg/m^2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 200 mg IV Q3W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Participants who experienced disease progression on docetaxel may have been eligible to crossover to receive pembrolizumab.</description>
    <arm_group_label>Pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_label>Pembrolizumab 10 mg/kg</arm_group_label>
    <arm_group_label>Docetaxel 75 mg/m^2</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Participants who initially receive docetaxel may be eligible to crossover to receive pembrolizumab.</description>
    <arm_group_label>Docetaxel 75 mg/m^2</arm_group_label>
    <other_name>TAXOTERE®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Life expectancy of at least 3 months

          -  Histologically- or cytologically-confirmed diagnosis of NSCLC that is anti-programmed
             cell death ligand 1 (PD-L1) positive per central laboratory review

          -  At least one bi-dimensional measurable lesion

          -  Radiographic progression after treatment with at least 2 cycles of a
             platinum-containing doublet

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

        Exclusion Criteria:

          -  Prior therapy with docetaxel for NSCLC

          -  Receiving systemic steroid therapy within 3 days prior to the first dose of study
             treatment or receiving any other form of immunosuppressive medication

          -  Currently participating or has participated in a study using an investigational
             antineoplastic agent or device within 30 days of first dose

          -  Expected to require any other form of systemic or localized antineoplastic therapy
             while on trial

          -  History of allogeneic tissue/solid organ transplant

          -  Prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g.,
             cetuximab), major surgery within 3 weeks of the first dose of study drug; received
             thoracic radiation therapy of &gt;30 Gy within 6 months of the first dose of study drug;
             received prior tyrosine kinase inhibitor therapy or completed palliative radiotherapy
             within 7 days of the first dose of study drug

          -  Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2,
             anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4
             (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically
             targeting T-cell co-stimulation or checkpoint pathways), or took part in another
             pembrolizumab trial

          -  Known history of prior malignancy, with the exception of basal cell carcinoma of the
             skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ
             cervical cancer, and has undergone potentially curative therapy with no evidence of
             that disease recurrence for 5 years since initiation of that therapy

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Active autoimmune disease, or a documented history of autoimmune disease, or a
             syndrome that requires systemic steroids or immunosuppressive agents

          -  Interstitial lung disease, or history of pneumonitis requiring systemic steroids for
             treatment

          -  Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis
             C

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial through 120 days after last dose of pembrolizumab or
             180 days after last dose of docetaxel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.</citation>
    <PMID>26712084</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <results_first_submitted>September 15, 2016</results_first_submitted>
  <results_first_submitted_qc>November 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants who had non-small cell lung cancer (NSCLC) and whose tumors were assessed as being programmed cell death ligand 1 (PD-L1) positive were recruited for this study.</recruitment_details>
      <pre_assignment_details>The data cut-off date for this results disclosure was 30 Sep 2015, at which time 159 participants were continuing on study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pembrolizumab 2 mg/kg</title>
          <description>Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 2 years.</description>
        </group>
        <group group_id="P2">
          <title>Pembrolizumab 10 mg/kg</title>
          <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
        </group>
        <group group_id="P3">
          <title>Docetaxel 75 mg/m^2</title>
          <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="346"/>
                <participants group_id="P3" count="343"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="339"/>
                <participants group_id="P2" count="343"/>
                <participants group_id="P3" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="346"/>
                <participants group_id="P3" count="328"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="113"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Continuing in Study</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded from Efficacy Analysis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-To-Treat population consisted of all participants who were randomized. Participants were included in the treatment group to which they were randomized. Data from one participant in the Pembrolizumab 2 mg/kg group were excluded from efficacy analyses due to Good Clinical Practice (GCP) non-compliance.</population>
      <group_list>
        <group group_id="B1">
          <title>Pembrolizumab 2 mg/kg</title>
          <description>Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
        </group>
        <group group_id="B2">
          <title>Pembrolizumab 10 mg/kg</title>
          <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
        </group>
        <group group_id="B3">
          <title>Docetaxel 75 mg/m^2</title>
          <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="344"/>
            <count group_id="B2" value="346"/>
            <count group_id="B3" value="343"/>
            <count group_id="B4" value="1033"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="9.6"/>
                    <measurement group_id="B2" value="62.3" spread="9.7"/>
                    <measurement group_id="B3" value="61.6" spread="9.8"/>
                    <measurement group_id="B4" value="62.0" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="399"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PD-L1 Tumor Expression Status</title>
          <description>PD-L1 expression was evaluated by immunohistochemistry (IHC) assay with a newly obtained tumor tissue with biopsy. If PD-L1 expression was observed in &gt;1%, but ≤49% of tumor cells, a participant was categorized as weakly PD-L1 positive. If PD-L1 expression was observed in ≥50% of tumor cells, a participant was categorized as strongly PD-L1 positive.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Weakly PD-L1 Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly PD-L1 Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from randomization to death due to any cause. OS was analyzed using the Kaplan-Meier method and is reported in months.</description>
        <time_frame>Through database cutoff date of 30 Sep 2015 (Approximately 23 months)</time_frame>
        <population>The Intent-To-Treat population consisted of all participants who were randomized and were included in the efficacy analysis. Participants were included in the treatment group to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab 2 mg/kg</title>
            <description>Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab 10 mg/kg</title>
            <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from randomization to death due to any cause. OS was analyzed using the Kaplan-Meier method and is reported in months.</description>
          <population>The Intent-To-Treat population consisted of all participants who were randomized and were included in the efficacy analysis. Participants were included in the treatment group to which they were randomized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly PD-L1 Positive (n=139,151,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="10.4">Upper limit OS not reached.</measurement>
                    <measurement group_id="O2" value="17.3" lower_limit="11.8">Upper limit OS not reached.</measurement>
                    <measurement group_id="O3" value="8.2" lower_limit="6.4" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All PD-L1 Positive (n=344, 346, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="9.4" upper_limit="11.9"/>
                    <measurement group_id="O2" value="12.7" lower_limit="10.0" upper_limit="17.3"/>
                    <measurement group_id="O3" value="8.5" lower_limit="7.5" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with strongly PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00024</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>Numerator=Pembrolizumab 2 mg/kg Denominator=Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with strongly PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
            <estimate_desc>Numerator=Pembrolizumab 10 mg/kg Denominator=Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00076</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>Numerator=Pembrolizumab 2 mg/kg Denominator=Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>Numerator=Pembrolizumab 10 mg/kg Denominator=Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</title>
        <description>PFS was defined as the time from the first day of study treatment to the first documented disease progression per RECIST 1.1 based on blinded independent central radiologists’ review or death due to any cause, whichever occurred first. Using RECIST 1.1, progressive disease was defined as either a 20% relative increase in the sum of diameters of target lesions, taking as reference the smallest sum on study OR an absolute increase of &gt;5 mm in the sum of lesions, OR the appearance of new lesions. PFS was analyzed using the Kaplan-Meier method and is reported in months.</description>
        <time_frame>Through database cutoff date of 30 Sep 2015 (Approximately 23 months)</time_frame>
        <population>The ITT population consisted of all participants who were randomized and included in the efficacy analysis. Participants were included in the treatment group to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab 2 mg/kg</title>
            <description>Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab 10 mg/kg</title>
            <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</title>
          <description>PFS was defined as the time from the first day of study treatment to the first documented disease progression per RECIST 1.1 based on blinded independent central radiologists’ review or death due to any cause, whichever occurred first. Using RECIST 1.1, progressive disease was defined as either a 20% relative increase in the sum of diameters of target lesions, taking as reference the smallest sum on study OR an absolute increase of &gt;5 mm in the sum of lesions, OR the appearance of new lesions. PFS was analyzed using the Kaplan-Meier method and is reported in months.</description>
          <population>The ITT population consisted of all participants who were randomized and included in the efficacy analysis. Participants were included in the treatment group to which they were randomized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly PD-L1 Positive (n=139, 151, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="4.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.1" upper_limit="8.1"/>
                    <measurement group_id="O3" value="4.1" lower_limit="3.6" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All PD-L1 Positive (n=344, 346, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.1" upper_limit="4.1"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.6" upper_limit="4.3"/>
                    <measurement group_id="O3" value="4.0" lower_limit="3.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with strongly PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00009</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>Numerator=Pembrolizumab 2 mg/kg Denominator=Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with strongly PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00007</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
            <estimate_desc>Numerator=Pembrolizumab 10 mg/kg Denominator=Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06758</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Numerator=Pembrolizumab 2 mg/kg Denominator=Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00462</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Numerator=Pembrolizumab 10 mg/kg Denominator=Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Adverse Events (AEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the study drug, was also an AE. After discontinuation of study drug, each participant was monitored for a minimum of 30 days after last dose of study drug (serious AEs were monitored for up to 90 days after last dose of study drug).</description>
        <time_frame>AEs: Up to 30 days after last dose of study drug (Up to approximately 24 months). Serious AEs: Up to 90 days after last dose of study drug (Up to approximately 27 months).</time_frame>
        <population>The All Participants As Treated (APAT) population consisted of all participants who received at least one dose of study drug. Participants were included in the treatment group based on the study treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab 2 mg/kg</title>
            <description>Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab 10 mg/kg</title>
            <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Adverse Events (AEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the study drug, was also an AE. After discontinuation of study drug, each participant was monitored for a minimum of 30 days after last dose of study drug (serious AEs were monitored for up to 90 days after last dose of study drug).</description>
          <population>The All Participants As Treated (APAT) population consisted of all participants who received at least one dose of study drug. Participants were included in the treatment group based on the study treatment they received.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6"/>
                    <measurement group_id="O2" value="96.2"/>
                    <measurement group_id="O3" value="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Discontinuing Study Drug Due to AEs</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the study drug, was also an AE.</description>
        <time_frame>Up to approximately 23 months</time_frame>
        <population>The APAT population consisted of all participants who received at least one dose of study drug. Participants were included in the treatment group based on the study treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab 2 mg/kg</title>
            <description>Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab 10 mg/kg</title>
            <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Drug Due to AEs</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have a causal relationship with this treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the study drug, was also an AE.</description>
          <population>The APAT population consisted of all participants who received at least one dose of study drug. Participants were included in the treatment group based on the study treatment they received.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="343"/>
                <count group_id="O3" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="7.6"/>
                    <measurement group_id="O3" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR) by RECIST 1.1</title>
        <description>ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) based on blinded independent central radiologists' review using RECIST 1.1.</description>
        <time_frame>Through database cutoff date of 30 Sep 2015 (Approximately 23 months)</time_frame>
        <population>The ITT population consisted of all participants who were randomized and included in the efficacy analysis. Participants were included in the treatment group to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab 2 mg/kg</title>
            <description>Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab 10 mg/kg</title>
            <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR) by RECIST 1.1</title>
          <description>ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) based on blinded independent central radiologists' review using RECIST 1.1.</description>
          <population>The ITT population consisted of all participants who were randomized and included in the efficacy analysis. Participants were included in the treatment group to which they were randomized.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly PD-L1 Positive (n=139, 151, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="22.7" upper_limit="38.6"/>
                    <measurement group_id="O2" value="29.1" lower_limit="22.0" upper_limit="37.1"/>
                    <measurement group_id="O3" value="7.9" lower_limit="4.1" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All PD-L1 Positive (n=344, 346, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="14.1" upper_limit="22.5"/>
                    <measurement group_id="O2" value="18.5" lower_limit="14.5" upper_limit="23.0"/>
                    <measurement group_id="O3" value="9.3" lower_limit="6.5" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>In participants with strongly PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66608</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.7</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
            <estimate_desc>This is an adjusted risk difference estimated by stratified Miettinen &amp; Nurminen method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with strongly PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>22.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.0</ci_lower_limit>
            <ci_upper_limit>30.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00045</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>8.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.6</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In participants with PD-L1 positive tumors</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00024</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in Percentages</param_type>
            <param_value>9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.1</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) by RECIST 1.1</title>
        <description>DOR is measured from the time measurement criteria were first met for CR/PR (whichever was first recorded) until the first date that recurrent or progressive disease was objectively documented (taking as reference for progressive disease the smallest measurements recorded on study). DOR was censored at the last tumor assessment date if a responder did not have PD or death. Non-responders were not included in the analysis. DOR was analyzed using the Kaplan-Meier method and is reported in weeks.</description>
        <time_frame>Through database cutoff date of 30 Sep 2015 (Approximately 23 months)</time_frame>
        <population>The ITT population consisted of all participants who were randomized. Participants were included in the treatment group to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab 2 mg/kg</title>
            <description>Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab 10 mg/kg</title>
            <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
          </group>
          <group group_id="O3">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) by RECIST 1.1</title>
          <description>DOR is measured from the time measurement criteria were first met for CR/PR (whichever was first recorded) until the first date that recurrent or progressive disease was objectively documented (taking as reference for progressive disease the smallest measurements recorded on study). DOR was censored at the last tumor assessment date if a responder did not have PD or death. Non-responders were not included in the analysis. DOR was analyzed using the Kaplan-Meier method and is reported in weeks.</description>
          <population>The ITT population consisted of all participants who were randomized. Participants were included in the treatment group to which they were randomized.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly PD-L1 Positive (n=139, 151, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="3">Median DOR: Not reached. DOR upper limit: No progressive disease by the time of last disease assessment.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="9">Median DOR: Not reached. DOR upper limit: No progressive disease by the time of last disease assessment.</measurement>
                    <measurement group_id="O3" value="35" lower_limit="9" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All PD-L1 Positive (n=344, 346, 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="3">Median DOR: Not reached. DOR upper limit: No progressive disease by the time of last disease assessment.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="9">Median DOR: Not reached. DOR upper limit: No progressive disease by the time of last disease assessment.</measurement>
                    <measurement group_id="O3" value="27" lower_limit="6">DOR upper limit: No progressive disease by the time of last disease assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: Up to 30 days after last dose of study drug (Up to approximately 24 months). Serious AEs: Up to 90 days after last dose of study drug (Up to approximately 27 months).</time_frame>
      <desc>The APAT population consisted of all participants who received at least one dose of study drug. Participants were included in the treatment group based on the study treatment they received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pembrolizumab 2 mg/kg</title>
          <description>Participants received pembrolizumab 2 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
        </group>
        <group group_id="E2">
          <title>Pembrolizumab 10 mg/kg</title>
          <description>Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.</description>
        </group>
        <group group_id="E3">
          <title>Docetaxel 75 mg/m^2</title>
          <description>Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years. Participants who experienced disease progression, may have been eligible to crossover to receive pembrolizumab 2 mg/kg Q3W.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="339"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>External ear cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Phlebitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="339"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="343"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyopneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonitis chemical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Post procedural urine leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Aspiration bronchial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Toxic leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bladder hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="339"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="339"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="343"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Superior vena cava occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="297" subjects_at_risk="339"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="343"/>
                <counts group_id="E3" subjects_affected="276" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="339"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="343"/>
                <counts group_id="E3" events="68" subjects_affected="59" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="339"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="101" subjects_affected="47" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="339"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="343"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="339"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="343"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="339"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="343"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="59" subjects_affected="54" subjects_at_risk="339"/>
                <counts group_id="E2" events="54" subjects_affected="49" subjects_at_risk="343"/>
                <counts group_id="E3" events="44" subjects_affected="37" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="73" subjects_affected="53" subjects_at_risk="339"/>
                <counts group_id="E2" events="48" subjects_affected="42" subjects_at_risk="343"/>
                <counts group_id="E3" events="106" subjects_affected="79" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="84" subjects_affected="73" subjects_at_risk="339"/>
                <counts group_id="E2" events="75" subjects_affected="65" subjects_at_risk="343"/>
                <counts group_id="E3" events="70" subjects_affected="57" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="339"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="343"/>
                <counts group_id="E3" events="69" subjects_affected="46" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="52" subjects_affected="44" subjects_at_risk="339"/>
                <counts group_id="E2" events="52" subjects_affected="43" subjects_at_risk="343"/>
                <counts group_id="E3" events="36" subjects_affected="31" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="38" subjects_at_risk="339"/>
                <counts group_id="E2" events="48" subjects_affected="37" subjects_at_risk="343"/>
                <counts group_id="E3" events="66" subjects_affected="47" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="339"/>
                <counts group_id="E2" events="35" subjects_affected="28" subjects_at_risk="343"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="107" subjects_affected="91" subjects_at_risk="339"/>
                <counts group_id="E2" events="92" subjects_affected="79" subjects_at_risk="343"/>
                <counts group_id="E3" events="120" subjects_affected="99" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="339"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="343"/>
                <counts group_id="E3" events="36" subjects_affected="33" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="40" subjects_at_risk="339"/>
                <counts group_id="E2" events="52" subjects_affected="34" subjects_at_risk="343"/>
                <counts group_id="E3" events="54" subjects_affected="41" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="339"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="343"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="339"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="343"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="339"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="343"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="339"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="44" subjects_affected="25" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="339"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="343"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="339"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E3" events="28" subjects_affected="16" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="110" subjects_affected="95" subjects_at_risk="339"/>
                <counts group_id="E2" events="82" subjects_affected="72" subjects_at_risk="343"/>
                <counts group_id="E3" events="82" subjects_affected="70" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="50" subjects_affected="40" subjects_at_risk="339"/>
                <counts group_id="E2" events="40" subjects_affected="35" subjects_at_risk="343"/>
                <counts group_id="E3" events="32" subjects_affected="27" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="35" subjects_at_risk="339"/>
                <counts group_id="E2" events="39" subjects_affected="36" subjects_at_risk="343"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="339"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="343"/>
                <counts group_id="E3" events="16" subjects_affected="10" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="339"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="343"/>
                <counts group_id="E3" events="48" subjects_affected="34" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="339"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="343"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="339"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="343"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="339"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="343"/>
                <counts group_id="E3" events="24" subjects_affected="18" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="38" subjects_affected="36" subjects_at_risk="339"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="343"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="339"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="343"/>
                <counts group_id="E3" events="38" subjects_affected="36" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="339"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="343"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="339"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="343"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="339"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="343"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="83" subjects_affected="72" subjects_at_risk="339"/>
                <counts group_id="E2" events="72" subjects_affected="58" subjects_at_risk="343"/>
                <counts group_id="E3" events="46" subjects_affected="42" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="87" subjects_affected="79" subjects_at_risk="339"/>
                <counts group_id="E2" events="85" subjects_affected="71" subjects_at_risk="343"/>
                <counts group_id="E3" events="64" subjects_affected="58" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="23" subjects_at_risk="339"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="343"/>
                <counts group_id="E3" events="29" subjects_affected="20" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="339"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="343"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="339"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="343"/>
                <counts group_id="E3" events="107" subjects_affected="105" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="339"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="343"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="37" subjects_affected="32" subjects_at_risk="339"/>
                <counts group_id="E2" events="58" subjects_affected="41" subjects_at_risk="343"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="339"/>
                <counts group_id="E2" events="64" subjects_affected="53" subjects_at_risk="343"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

